Alembic Pharmaceuticals Q3 FY26 Investor Presentation

Alembic Pharmaceuticals Limited reports Q3 FY26 results with total revenue of INR 18.76 billion, driven by growth across India Branded (6% YoY), US Generics (6% YoY), and Ex-US Generics (36% YoY) segments. EBITDA reached INR 3.08 billion with 16% margin, while net profit before tax (before exceptional items) grew 33% YoY to INR 2.04 billion.